SOURCE: MMIT Analytics, as of 12/18/18
Wednesday, January 2, 2019
The FDA last month approved Shire's Montegrity for...
...the treatment of chronic
idiopathic constipation, a market that is currently dominated by Allergan's
Linzess. 58% of covered lives have preferred access to Linzess. Another recent
competitor, Synergy's Trulance, holds preferred status for only 4% of covered
lives, and is not covered for another 26%.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment